about
Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable anginaAssessment of reproducibility in depletion and enrichment workflows for plasma proteomics using label-free quantitative data-independent LC-MS.Qualitative and quantitative characterization of plasma proteins when incorporating traveling wave ion mobility into a liquid chromatography-mass spectrometry workflow for biomarker discovery: use of product ion quantitation as an alternative data aProlonged stability of endogenous cardiotrophin-1 in whole blood.Searching for biomarkers of heart failure in the mass spectra of blood plasma.Improving the diagnostic accuracy of N-terminal B-type natriuretic peptide in human systolic heart failure by plasma profiling using mass spectrometry.Biomarkers in acute myocardial infarction.C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.Abnormal Na+/H+ antiporter phenotype and turnover of immortalized lymphoblasts from type 1 diabetic patients with nephropathyThe uroguanylin system and human disease.Proteinase 3 and prognosis of patients with acute myocardial infarction.A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction.Improved analysis of vitamin D metabolites in plasma using liquid chromatography tandem mass spectrometry, and its application to cardiovascular research.Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP.Reduction in plasma concentrations of N terminal pro B type natriuretic peptide following percutaneous coronary interventionSafe use of brain natriuretic protein to rule out the diagnosis of heart failure depends on the selection of cut off value.Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trialCirculating microRNAs and Outcome in Patients with Acute Heart Failure.Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction.Prognostic Role of Molecular Forms of B-Type Natriuretic Peptide in Acute Heart Failure.Is admission blood glucose concentration a more powerful predictor of mortality after myocardial infarction than diabetes diagnosis? A retrospective cohort study.Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort studyAldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction.Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarctionGrowth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy.Protein Kinase C Epsilon Contributes to NADPH Oxidase Activation in a Pre-Eclampsia Lymphoblast Cell Model.Activation of a novel natriuretic endocrine system in humans with heart failure.A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.Natriuretic peptides in common valvular heart disease.Prognostic significance of adrenomedullin in patients with heart failure and with myocardial infarction.Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized controlled trial.Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure.Desensitisation of native and recombinant human urotensin-II receptors.Gender and renal function influence plasma levels of copeptin in healthy individuals.Coronary angiography in worsening heart failure: determinants, findings and prognostic implications.Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure.Growth hormone for risk stratification and effects of therapy in acute myocardial infarction.Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure: A GREAT Network Study.
P50
Q24683609-096C0455-321A-4468-B71F-E05CD604ECAEQ30685445-E08FD114-02B4-45EA-8C8A-AE6AE7C9666CQ30727415-2F0EAF9A-FD5D-42AB-9B03-26ED6102AFC0Q32067854-365D380F-369F-4A18-B0E4-DA6D59AD969AQ33260891-C00EA9BB-B764-407A-B3F6-246C7932B0D7Q33290716-981B4E23-578A-4107-8A16-397F66AFF207Q33596823-C185FD83-122B-4F2F-9FB2-822FED5E43D4Q34003454-D5BEBC8B-D3CF-4160-A3C1-290B87BC9608Q34138706-959048C7-DBAB-4F46-A94B-EFBAF901DEA4Q34154384-A0548FFD-3FD4-49D5-BF17-7BD4911698E8Q34293073-50214200-3F41-4885-8ECB-AC02D4B8ACC0Q34394925-FDCD5FDB-56C8-40C8-993F-BCCAED1F2E96Q34962538-731843E1-A43F-4252-9C8C-1A4888C63CE3Q35174198-292D4595-E4A7-4CB1-AA00-2B7877BCADC5Q35375245-000CF463-4875-40FD-9528-386E85E453C2Q35583067-097CF75D-E578-4388-BAB9-C210A8C14FCFQ35584481-01CA1072-4BDC-482B-BF7F-60CC7BDF9962Q35770965-BB71FC0F-65BF-4546-88AF-806D74199B44Q35845355-785122AF-83DB-429D-A065-E87457798A45Q36014190-08BFD42B-CB1E-4B4B-94E8-7D5116AAE1AFQ36276189-D899C474-0B25-4E56-852E-747496A6F0D8Q36307110-831902F6-CD5A-4257-9C38-BA6DEF530CC3Q36387323-A14E9D8F-DEFA-4982-95B1-D70217EA836FQ36800757-15D1A4FF-6E3F-4A1C-9394-503A88941B7AQ37083030-CC6F4D2C-6080-439D-B676-CE7BD75303EFQ37420336-4C6EAA18-9E79-4B38-8CCF-35F0156828ABQ37441560-8C9EA4C6-B41E-4393-9335-29C49A31E193Q37461939-C9C126F3-BF31-49D5-BD5E-0C85ED95CB09Q37737587-72062391-C835-488E-B60F-7D93530E4986Q37743962-594C90AD-11FB-42E4-8A26-0DCA02001F5EQ38355932-DC76B3F8-EC07-435B-89B6-D5068BCBB939Q38411213-A8E1E7BB-6C62-4B79-8558-ECBF8A3B47DFQ38442410-763D47A0-7531-4737-801F-58F60FD08A60Q39812797-F11D3896-BAC1-40C8-A7B7-9EB8206161BEQ40067883-99E812FD-C268-4D28-8A5E-7B21116EBAD8Q40086592-9FF44914-B3A4-4153-B7D4-328F7D48CC3EQ40173081-CC19094D-1B9C-4900-B580-388CE19A29BCQ40313672-7F68E51A-F8A3-4E16-9D91-0CCE13827B97Q40365832-5D716486-8C3A-43F7-A537-6B3D3370E556Q40393977-EABC7F64-4708-4F1F-9A11-CBFAADC887F0
P50
description
researcher ORCID ID = 0000-0002-6553-5749
@en
wetenschapper
@nl
name
Leong L Ng
@ast
Leong L Ng
@en
Leong L Ng
@nl
type
label
Leong L Ng
@ast
Leong L Ng
@en
Leong L Ng
@nl
prefLabel
Leong L Ng
@ast
Leong L Ng
@en
Leong L Ng
@nl
P21
P31
P496
0000-0002-6553-5749